New tool in fight against malaria

Modifying a class of molecules called pantothenamides to be more stable in humans could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Image: pxhere.com

Redesigning molecules originally developed to treat the skin disease psoriasis could lead to an effective new drug against malaria, according to an international team of researchers. The team modified a class of molecules called pantothenamides to increase their stability in humans. The new compounds stop the malaria parasite from replicating in infected humans and from being transmitted to mosquitoes, and are effective against malaria parasites resistant to currently available drugs.

A paper describing this new class of modified pantothenamides appears online Sept. 18 in the journal Science Translational Medicine.

Malaria is a major global health concern, with around 216 million cases and 400,000 deaths annually. The deadliest form of the disease is caused by the parasite Plasmodium falciparum, which is transmitted to humans from the bite of an infected Anopheles mosquito. Because many Plasmodium parasites have developed resistance to the most common drugs used against them, there is a pressing need for effective new treatment options.

“We have known for a long time that pantothenamides are extremely potent against the malaria parasite, but they become unstable within biological fluids because an enzyme clips them apart before they can act,” said Manuel Llinás, professor of biochemistry and molecular biology and of chemistry at Penn State, and an author of the paper. “Our team of collaborators, led by Koen Dechering at TropIQ Health Sciences and Joost Schalkwijk at Radboud University Medical Center in the Netherlands, found that changing a chemical bond in a pantothenamide molecule prevents this clipping, making it viable for use as a new antimalarial drug.”

The team found that the modified pantothenamide molecules not only interfere with the development of the malaria parasite during its asexual growth phase in the blood but also prevent transmission of the sexual form of the parasite from human blood to mosquitoes.

“By also preventing the transmission of malaria parasites from infected people into mosquitoes, these pantothenamides can reduce the chances that mosquitoes will be infectious to others,” said Llinás. “It is currently widely accepted that next-generation antimalarial drugs must target the parasite at multiple stages to both cure the disease in an infected individual and prevent its spread to others.”

Llinás and Erik Allman, postdoctoral scholar at Penn State at the time of the research, investigated exactly how the four most potent molecules in the compound class kill the malaria parasite. Specifically, they examined how these compounds affect the parasite’s metabolism while growing in human blood.

The team discovered that, because the pantothenamide molecule closely resembles the essential vitamin B5, it is mistakenly taken in and metabolized by the parasite. This leads to the formation of molecular analogues, or antimetabolites, which decrease the parasite’s production of acetyl-CoA, a compound critical for its survival.

“The molecule has a mechanism of action that hasn’t been used before,” said Dechering. “This means that there’s no resistance to the drug as yet, and it is effective against many forms of malaria. Because parasite resistance to malaria drugs is a major problem worldwide, we are very close to a breakthrough.”

“Pantothenamides have a simple chemistry, so they are easy and inexpensive to make,” said Llinás, “And we now know their mode of action, which we don’t always know before moving into drug development. This makes pantothenamides excellent candidates for further development and eventual clinical trials.”

In addition to Penn State, Radboud University Medical Center, and TropIQ Health Sciences, the collaboration also includes researchers from St. Jude’s Children’s Research Hospital, Chiralix in the Netherlands, XenoGesis in the United Kingdom, the Swiss Tropical and Public Health Institute in Switzerland, the University of Basil in Switzerland, the Art of Discovery in Spain, Medicines for Malaria Venture in Switzerland, and Hermkens Pharma Consultancy in the Netherlands.

Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don't put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources.
It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!

Mirage News . All timestamps on this site are AEST/AEDT and all times in the articles are local times unless indicated otherwise.

All trademarks and rights are owned by their respective owners. All content is used for news reporting purposes.
For news reporting purposes, we rely on fair use (fair dealing) [1] [2]for textual and media content to keep the public informed on the developments. If you are a person mentioned in the story or you are a copyright holder and believe that any content should be removed, revised or taken down, please contact us. View the disclaimer page here